Should the FDA Do More to Increase Transparency?
An FDA pilot program to promote transparency in clinical studies falls short of similar efforts by its European and Canadian counterparts.
Hematologic Cancer
HEMATOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Unlocking the Potential of Biosimilars in Community Oncology
Full adoption of biosimilars will require proper provider and patient education, payer coverage navigation support, and streamlined workflows. -
Can Patient-Derived Organoids Help Oncologists Make Treatment Decisions?
Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients. -
Intravenous Busulfan Plus Melphalan vs Melphalan Alone as a Conditioning Regimen in Multiple Myeloma: Is There a Difference?
There appears to be accumulating evidence to support the routine use of busulfan plus melphalan as a conditioning regimen. -
Data Mining to Develop Mutation-Specific Treatments in Acute Myeloid Leukemia
Integrating mutation-specific data across repositories and portals may lead to novel therapeutically actionable insights for acute myeloid leukemia.
HEMATOLOGIC CANCER NEWS
No Correlation Between SF3B1 Mutation in Myelodysplastic Syndrome and Overall Survival
Checklist Ensures Adherence to Recommended CAR-T Cell Administration Processes
Nanatinostat Gets Orphan Drug Designation for EBV-Associated Cancers
Presence of Autoimmune Diseases May Increase Risk for Diffuse Large B Cell, Marginal Zone Lymphomas
Support for Multimodality Therapy in Some Patients With Follicular Lymphoma
MORE HEMATOLOGIC CANCER INFORMATION
A 47-Year-Old Woman with Pancytopenia After Treatment with Radioiodine Therapy
DARZALEX (daratumumab) for Multiple Myeloma
ZOLINZA (vorinostat) for Cutaneous T-cell Lymphoma
NINLARO (ixazomib) for Multiple Myeloma
GAZYVA (obinutuzumab) for Follicular Lymphoma
VENCLEXTA (venetoclax) for Chronic Lymphocytic Leukemia
EMPLICITI (elotuzumab) for Multiple Myeloma
SPRYCEL (dasatinib) for Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia
Want to read more?
Please login or register first to view this content.
Next post in Hematologic Cancers
